Slingshot members are tracking this event:

Bluebird Bio (BLUE) to complete Phase 1/2 study of LentiGlobin BB305 to subjects with beta-thalassemia major or severe sickle cell disease in December 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 1/2 Study, Lentiglobin, Lentiglobin Bb305, Beta-thalassemia, Sickle Cell Disease